# Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

> **NCT03329989** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 158 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy
- Cellulite

## Interventions

- **BIOLOGICAL:** Collagenase Clostridium Histolyticum

## Key facts

- **NCT ID:** NCT03329989
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-17
- **Primary completion:** 2018-09-05
- **Final completion:** 2018-09-05
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329989, "Safety and Effectiveness of EN3835 in the Treatment of EFP in Women". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03329989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*